Search This Blog

Monday, February 1, 2021

Novavax (NVAX) Now A Premier COVID Vaccine Company: Jefferies

 

Jefferies analyst Kelechi Chikere reiterated a Buy rating and $200.00 price target on Novavax (NASDAQ: NVAX).  Thinks FDA EUA possible.

https://www.streetinsider.com/Analyst+Comments/Novavax+%28NVAX%29+Is+Now+A+Premier+COVID+Vaccine+Company%2C+Jefferies+Thinks+FDA+EUA+Possible/17884735.html

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)